References
- Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br J Cancer. 2018;119(7):785–92. doi:https://doi.org/10.1038/s41416-018-0264-x
- Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60. doi:https://doi.org/10.1056/NEJMra0804588
- Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EMM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62(5):787–96. doi:https://doi.org/10.1136/gutjnl-2012-302504
- Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. doi:https://doi.org/10.1016/s0140-6736(19)32319-0
- Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol. 2016;30(1):119–31. doi:https://doi.org/10.1016/j.bpg.2016.02.009
- Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690–704. doi:https://doi.org/10.1038/s41575-019-0209-8
- Stone TW, McPherson M, Gail Darlington L. Obesity and cancer: existing and new hypotheses for a causal connection. EBioMedicine. 2018;30:14–28. doi:https://doi.org/10.1016/j.ebiom.2018.02.022
- Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244–60.e16. doi:https://doi.org/10.1053/j.gastro.2014.12.035
- Gao Z, Guo B, Gao R, Zhu Q, Wu W, Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep. 2015;12(4):6119–27. doi:https://doi.org/10.3892/mmr.2015.4124
- Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. Jama. 2015;313(11):1133–42.:doi:https://doi.org/10.1001/jama.2015.1815
- Rejhova A, Opattova A, Čumová A, Slíva D, Vodička P. Natural compounds and combination therapy in colorectal cancer treatment. Eur J Med Chem. 2018;144:582–94. doi:https://doi.org/10.1016/j.ejmech.2017.12.039
- Almasaudi AS, McSorley ST, Edwards CA, McMillan DC. The relationship between body mass index and short term postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;121:68–73. doi:https://doi.org/10.1016/j.critrevonc.2017.12.004
- Hendler R, Zhang Y. Probiotics in the treatment of colorectal cancer. Medicines (Basel). 2018;5(3):101. doi:https://doi.org/10.3390/medicines5030
- Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–29. doi:https://doi.org/10.1038/s41591-019-0439-x
- Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, et al. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164–85.:doi:https://doi.org/10.4161/gmic.1.3.12127
- Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7(9):503–14. doi:https://doi.org/10.1038/nrgastro.2010.117
- Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46 Suppl 2(Suppl 2):S104–S11, discussion S144-51. doi:https://doi.org/10.1086/523331
- Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2 Suppl):451S–5s. doi:https://doi.org/10.1093/ajcn/73.2.451s
- Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–79. doi:https://doi.org/10.1056/NEJMra1600266
- Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512–9. doi:https://doi.org/10.1016/s0140-6736(03)12489-0
- Gallimore AM, Godkin A. Epithelial barriers, microbiota, and colorectal cancer. N Engl J Med. 2013;368(3):282–4. doi:https://doi.org/10.1056/NEJMcibr1212341
- Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018;155(3):596–600. doi:https://doi.org/10.1053/j.gastro.2018.07.038
- Chong ES. A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action. World J Microbiol Biotechnol. 2014;30(2):351–74. doi:https://doi.org/10.1007/s11274-013-1499-6
- Mendes, MCS, Paulino DSM, Brambilla SR, Camargo JA, Persinoti GF, Carvalheira JBC. Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice.World J Gastroenterol. 2018;24(18):1995–2008. doi:https://doi.org/10.3748/wjg.v24.i18.1995
- Fotiadis CI, Stoidis CN, Spyropoulos BG, Zografos ED. Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol. 2008;14(42):6453–7. doi:https://doi.org/10.3748/wjg.14.6453
- Raman M, Ambalam P, Kondepudi KK, Pithva S, Kothari C, Patel AT, Purama RK, Dave JM, Vyas BRM. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes. 2013;4(3):181–92. doi:https://doi.org/10.4161/gmic.23919
- Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661–72. doi:https://doi.org/10.1038/nrmicro3344
- Jan G, Belzacq A-S, Haouzi D, Rouault A, Métivier D, Kroemer G, Brenner C. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 2002;9(2):179–88. doi:https://doi.org/10.1038/sj.cdd.4400935
- Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, Ikuta K, Akutsu H, Tanabe H, Kohgo Y. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7:12365. doi:https://doi.org/10.1038/ncomms12365
- Tabung FK, Liu L, Wang W, Fung TT, Wu K, Smith-Warner SA, Cao Y, Hu FB, Ogino S, Fuchs CS, et al. Association of dietary inflammatory potential with risk in men and women. JAMA Oncol. 2018;4(3):366–73.: doi:https://doi.org/10.1001/jamaoncol.2017.4844
- Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2020;39(3):789–819. doi:https://doi.org/10.1016/j.clnu.2019.04.004
- Molska M, Reguła J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019;11(10):2453. doi:https://doi.org/10.3390/nu1110
- Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12. doi:https://doi.org/10.1038/nrc3610
- Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018;6(1):121. doi:https://doi.org/10.1186/s40168-018-0494-4
- Uccello M, Malaguarnera G, Basile F, D'agata V, Malaguarnera M, Bertino G, Vacante M, Drago F, Biondi A. Potential role of probiotics on colorectal cancer prevention. BMC Surg. 2012;12 Suppl 1:S35 doi:https://doi.org/10.1186/1471-2482-12-s1-s35
- Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran LG. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol. 2017;8:1553 doi:https://doi.org/10.3389/fimmu.2017.01553
- Irecta-Najera CA, Del Rosario Huizar-Lopez M, Casas-Solis J, Castro-Felix P, Santerre A. Protective effect of Lactobacillus casei on DMH-induced colon carcinogenesis in mice. Probiotics Antimicrob Proteins. 2017;9(2):163–71. doi:https://doi.org/10.1007/s12602-017-9253-2
- Verma A, Shukla G. Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. Nutr Cancer. 2013;65(1):84–91. doi:https://doi.org/10.1080/01635581.2013.741746
- Lucas C, Barnich N, Nguyen HTT. Microbiota, inflammation and colorectal cancer. Int J Mol Sci. 2017;18(6):1310. doi:https://doi.org/10.3390/ijms18061310
- Franz CM, Huch M, Abriouel H, Holzapfel W, Galvez A. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol. 2011;151(2):125–40. doi:https://doi.org/10.1016/j.ijfoodmicro.2011.08.014
- Chung I-C, OuYang C-N, Yuan S-N, Lin H-C, Huang K-Y, Wu P-S, Liu C-Y, Tsai K-J, Loi L-K, Chen Y-J, et al. Pretreatment with a heat-killed probiotic modulates the NLRP3 inflammasome and attenuates colitis-associated in mice. Nutrients. 2019;11(3):516. doi:https://doi.org/10.3390/nu11030
- Lenoir M, Del Carmen S, Cortes-Perez NG, Lozano-Ojalvo D, Muñoz-Provencio D, Chain F, Langella P, de Moreno de LeBlanc A, LeBlanc JG, Bermúdez-Humarán LG. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. 2016;51(9):862–73. doi:https://doi.org/10.1007/s00535-015-1158-9
- Rong J, Liu S, Hu C, Liu C. Single probiotic supplement suppresses colitis-associated colorectal tumorigenesis by modulating inflammatory development and microbial homeostasis. J Gastroenterol Hepatol. 2019;34(7):1182–92. doi:https://doi.org/10.1111/jgh.14516
- Gao C, Ganesh BP, Shi Z, Shah RR, Fultz R, Major A, Venable S, Lugo M, Hoch K, Chen X, et al. Gut microbe-mediated suppression of inflammation-associated colon carcinogenesis by luminal histamine production. Am J Pathol. 2017;187(10):2323–36.:doi:https://doi.org/10.1016/j.ajpath.2017.06.011
- Feng S, Song JD. Determination of β-glucuronidase in human colorectal carcinoma cell lines. World J Gastroenterol. 1997;3(4):251–2. doi:https://doi.org/10.3748/wjg.v3.i4.251
- Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, Poussa T, Mykkänen H, Korpela R. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int J Food Microbiol. 2008;128(2):406–10. doi:https://doi.org/10.1016/j.ijfoodmicro.2008.09.010
- Rao CV, Sanders ME, Indranie C, Simi B, Reddy BS. Prevention of colonic preneoplastic lesions by the probiotic Lactobacillus acidophilus NCFMTM in F344 rats. Int J Oncol. 1999;14:939–44. doi:https://doi.org/10.3892/ijo.14.5.939
- Hu J, Wang C, Ye L, Yang W, Huang H, Meng F, Shi S, Ding Z. Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice. J Biosci. 2015;40(2):269–79. doi:https://doi.org/10.1007/s12038-015-9518-4
- Chen ZY, Hsieh YM, Huang CC, Tsai CC. inhibitory effects of probiotic Lactobacillus on the growth of human colonic carcinoma cell line HT-29. Molecules. 2017;22(1):107. doi:https://doi.org/10.3390/molecules22010
- Escamilla J, Lane MA, Maitin V. Cell-free supernatants from probiotic Lactobacillus casei and Lactobacillus rhamnosus GG decrease colon cancer cell invasion in vitro. Nutr Cancer. 2012;64(6):871–8. doi:https://doi.org/10.1080/01635581.2012.700758
- Tojo R, Suárez A, Clemente MG, de los Reyes-Gavilán CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–76. doi:https://doi.org/10.3748/wjg.v20.i41.15163
- Bahmani S, Azarpira N, Moazamian E. Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742. Turk J Gastroenterol. 2019;30(9):835–42. doi:https://doi.org/10.5152/tjg.2019.18451
- Lee DK, Jang S, Kim MJ, Kim JH, Chung MJ, Kim KJ, Ha NJ. Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines. BMC Cancer. 2008;8:310. doi:https://doi.org/10.1186/1471-2407-8-310
- Fahmy CA, Gamal-Eldeen AM, El-Hussieny EA, Raafat BM, Mehanna NS, Talaat RM, Shaaban MT. Bifidobacterium longum suppresses murine colorectal cancer through the modulation of oncomiRs and tumor suppressor miRNAs. Nutr Cancer. 2019;71(4):688–700. doi:https://doi.org/10.1080/01635581.2019.1577984
- Mofid V, Izadi A, Mojtahedi SY, Khedmat L. Therapeutic and nutritional effects of synbiotic yogurts in children and adults: a clinical review. Probiotics Antimicrob Proteins. 2020;12(3):851–9. doi:https://doi.org/10.1007/s12602-019-09594-x
- Zhang K, Dai H, Liang W, Zhang L, Deng Z. Fermented dairy foods intake and risk of cancer. Int J Cancer. 2019;144(9):2099–108. doi:https://doi.org/10.1002/ijc.31959
- de Moreno de LeBlanc A, Perdigon G. Reduction of beta-glucuronidase and nitroreductase activity by yoghurt in a murine colon cancer model. Biocell. 2005;29:15–24.
- de Moreno de Leblanc A, Perdigon G. The application of probiotic fermented milks in cancer and intestinal inflammation. Proc Nutr Soc. 2010;69(3):421–8. doi:https://doi.org/10.1017/s002966511000159x
- de Moreno de LeBlanc A, Matar C, Perdigon G. The application of probiotics in cancer. Br J Nutr. 2007;98 Suppl 1(Suppl 1):S105–S10. doi:https://doi.org/10.1017/s0007114507839602
- Del Carmen S, de Moreno de LeBlanc A, LeBlanc JG. Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice. J Appl Microbiol. 2016;121(3):821–30. doi:https://doi.org/10.1111/jam.13213
- Kumar A, Singh NK, Sinha PR. Inhibition of 1,2-dimethylhydrazine induced colon genotoxicity in rats by the administration of probiotic curd. Mol Biol Rep. 2010;37(3):1373–6. doi:https://doi.org/10.1007/s11033-009-9519-1
- Khoury N, El-Hayek S, Tarras O, El-Sabban M, El-Sibai M, Rizk S. Kefir exhibits anti‑proliferative and pro‑apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion. Int J Oncol. 2014;45(5):2117–27. doi:https://doi.org/10.3892/ijo.2014.2635
- Tsai Y-L, Lin T-L, Chang C-J, Wu T-R, Lai W-F, Lu C-C, Lai H-C. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3. doi:https://doi.org/10.1186/s12929-018-0493-6
- Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006;5(10):1265–9. doi:https://doi.org/10.4161/cbt.5.10.3296
- Nakanishi S, Kataoka K, Kuwahara T, Ohnishi Y. Effects of high amylose maize starch and Clostridium butyricum on metabolism in colonic microbiota and formation of azoxymethane-induced aberrant crypt foci in the rat colon. Microbiol Immunol. 2003;47(12):951–8. doi:https://doi.org/10.1111/j.1348-0421.2003.tb03469.x
- Le Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP. Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against development in rats. Carcinogenesis. 2010;31(2):246–51. doi:https://doi.org/10.1093/carcin/bgp197
- Verma A, Shukla G. Synbiotic (Lactobacillus rhamnosus+Lactobacillus acidophilus+inulin) attenuates oxidative stress and colonic damage in 1,2 dimethylhydrazine dihydrochloride-induced colon carcinogenesis in Sprague-Dawley rats: a long-term study. Eur J Cancer Prev. 2014;23(6):550–9. doi:https://doi.org/10.1097/cej.0000000000000054
- Lin PY, Li SC, Lin HP, Shih CK. Germinated brown rice combined with Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis inhibits colorectal carcinogenesis in rats. Food Sci Nutr. 2019;7(1):216–24. doi:https://doi.org/10.1002/fsn3.864
- Piazuelo E, Lanas A. NSAIDS and gastrointestinal cancer. Prostaglandins Other Lipid Mediat. 2015;120:91–6. doi:https://doi.org/10.1016/j.prostaglandins.2015.06.001
- Mohania D, Kansal VK, Kruzliak P, Kumari A. Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum modulates the formation of aberrant crypt foci, mucin-depleted foci, and cell proliferation on 1,2-dimethylhydrazine-induced colorectal carcinogenesis in Wistar rats. Rejuvenation Res. 2014;17(4):325–33. doi:https://doi.org/10.1089/rej.2013.1537
- Movahedi M, Bishop DT, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol. 2015;33(31):3591–7.:doi:https://doi.org/10.1200/jco.2014.58.9952
- Sharaf LK, Sharma M, Chandel D, Shukla G. Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. BMC Cancer. 2018;18(1):1111. doi:https://doi.org/10.1186/s12885-018-4999-9
- Kaeid Sharaf L, Shukla G. Probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in conjunction with celecoxib (selective COX-2 inhibitor) modulated DMH-induced early experimental colon carcinogenesis. Nutr Cancer. 2018;70(6):946–55. doi:https://doi.org/10.1080/01635581.2018.1490783
- Terdiman JP, Johnson LK, Kim YS, Sleisenger MH, Gum JR, Hayes A, Weinberg VK, McQuaid KR. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci. 2009;54(11):2488–96. doi:https://doi.org/10.1007/s10620-009-0966-2
- Do E-j, Hwang SW, Kim S-Y, Ryu Y-M, Cho EA, Chung E-J, Park S, Lee HJ, Byeon J-S, Ye BD, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016;31(8):1453–61.: doi:https://doi.org/10.1111/jgh.13280
- Genaro SC, Lima de Souza Reis LS, Reis SK, Rabelo Socca EA, Favaro WJ. Probiotic supplementation attenuates the aggressiveness of chemically induced colorectal tumor in rats. Life Sci. 2019;237:116895. doi:https://doi.org/10.1016/j.lfs.2019.116895
- Baldwin C, Millette M, Oth D, Ruiz MT, Luquet F-M, Lacroix M. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer. 2010;62(3):371–8. doi:https://doi.org/10.1080/01635580903407197
- An J, Ha EM. Combination therapy of Lactobacillus plantarum supernatant and 5-fluouracil increases chemosensitivity in colorectal cancer cells. J Microbiol Biotechnol. 2016;26(8):1490–503. doi:https://doi.org/10.4014/jmb.1605.05024
- Fei Z, Lijuan Y, Xi Y, Wei W, Jing Z, Miao D, Shuwen H. Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. Gut Pathog. 2019;11(1):18. doi:https://doi.org/10.1186/s13099-019-0299-4
- Wang Y-H, Yao N, Wei K-K, Jiang L, Hanif S, Wang Z-X, Pei C-X. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr. 2016;70(11):1246–53. doi:https://doi.org/10.1038/ejcn.2016.102
- Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sanchez B, et al. Bifidobacteria and their health-promoting effects. Microbiol Spectr. 2017;5(3). doi:https://doi.org/10.1128/microbiolspec.BAD-0010-2016
- Peitsidou K, Karantanos T, Theodoropoulos GE. Probiotics, prebiotics, synbiotics: is there enough evidence to support their use in colorectal cancer surgery? Dig Surg. 2012;29(5):426–38. doi:https://doi.org/10.1159/000345580
- Golkhalkhali B, Paliany AS, Chin KF, Rajandram R. The roles of adjuvant supplements in colorectal cancer patients on chemotherapy – reaping benefits from metabolic crosstalk. Nutr Cancer. 2018;70(2):184–91. doi:https://doi.org/10.1080/01635581.2018.1412470
- Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18. doi:https://doi.org/10.1056/NEJMoa1403108
- Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356–62. doi:https://doi.org/10.1016/j.ctim.2015.03.008
- Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 2015;21(43):12234–48. doi:https://doi.org/10.3748/wjg.v21.i43.12234
- Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol. 1993;11(1):148–51. doi:https://doi.org/10.1200/JCO.1993.11.1.148
- Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–34. doi:https://doi.org/10.1038/sj.bjc.6603990
- Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley Des Varannes S, Le Vacon F, de La Cochetière MF. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis – current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409–21. doi:https://doi.org/10.1111/apt.12878
- Ciorba MA, Hallemeier CL, Stenson WF, Parikh PJ. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care. 2015;9(2):157–62. doi:https://doi.org/10.1097/spc.0000000000000134
- Van Sebille YZA, Stansborough R, Wardill HR, Bateman E, Gibson RJ, Keefe DM. Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr Oncol Rep. 2015;17(11):50. doi:https://doi.org/10.1007/s11912-015-0474-9
- Chang C-W, Liu C-Y, Lee H-C, Huang Y-H, Li L-H, Chiau J-SC, Wang T-E, Chu C-H, Shih S-C, Tsai T-H, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front Microbiol. 2018;9:983. doi:https://doi.org/10.3389/fmicb.2018.00983
- Yeung C-Y, Chan W-T, Jiang C-B, Cheng M-L, Liu C-Y, Chang S-W, Chiang Chiau J-S, Lee H-C. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS One. 2015;10(9):e0138746. doi:https://doi.org/10.1371/journal.pone.0138746
- Mi H, Dong Y, Zhang B, Wang H, Peter CCK, Gao P, Fu H, Gao Y. Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats. Cell Physiol Biochem. 2017;42(6):2330–41. doi:https://doi.org/10.1159/000480005
- Liu J, Huang XE. Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev. 2015;15(23):10241–4. doi:https://doi.org/10.7314/APJCP.2014.15.23.10241
- Ouyang X, Li Q, Shi M, Niu D, Song W, Nian Q, Li X, Ding Z, Ai X, Wang J, et al. Probiotics for preventing postoperative infection in colorectal cancer patients: a systematic review and meta-analysis. Int J Colorectal Dis. 2019;34(3):459–69.:doi:https://doi.org/10.1007/s00384-018-3214-4
- Anderson SW, Bazzell AF, Dains JE. An integrative review on the effect of prebiotics, probiotics, and synbiotics on infection after colorectal cancer surgery: 1.7 www.aornjournal.org/content/cme. AORN J. 2018;107(2):237–48. www.aornjournal.org/content/cme. doi:https://doi.org/10.1002/aorn.12033
- Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, Jiang Y, Zhang H, Yang Z, Wang Y, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in surgery – a double-blind study. Aliment Pharmacol Ther. 2011;33(1):50–63.: doi:https://doi.org/10.1111/j.1365-2036.2010.04492.x
- Kamboj M, Childers T, Sugalski J, Antonelli D, Bingener-Casey J, Cannon J, Cluff K, Davis KA, Dellinger EP, Dowdy SC, et al. Risk of surgical site infection (SSI) following colorectal resection is higher in patients with disseminated cancer: an NCCN member cohort study. Infect Control Hosp Epidemiol. 2018;39(5):555–62.:doi:https://doi.org/10.1017/ice.2018.40
- Aisu N, Tanimura S, Yamashita Y, Yamashita K, Maki K, Yoshida Y, Sasaki T, Takeno S, Hoshino S. Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. Exp Ther Med. 2015;10(3):966–72. doi:https://doi.org/10.3892/etm.2015.2640
- Wu X-D, Xu W, Liu M-M, Hu K-J, Sun Y-Y, Yang X-F, Zhu G-Q, Wang Z-W, Huang W. Efficacy of prophylactic probiotics in combination with antibiotics versus antibiotics alone for colorectal surgery: a meta-analysis of randomized controlled trials. J Surg Oncol. 2018;117(7):1394–404. doi:https://doi.org/10.1002/jso.25038
- Lundell L. Use of probiotics in abdominal surgery. Dig Dis. 2011;29(6):570–3. doi:https://doi.org/10.1159/000332984
- Kinross JM, Markar S, Karthikesalingam A, Chow A, Penney N, Silk D, Darzi A. A meta-analysis of probiotic and synbiotic use in elective surgery: does nutrition modulation of the gut microbiome improve clinical outcome? JPEN J Parenter Enteral Nutr. 2013;37(2):243–53. doi:https://doi.org/10.1177/0148607112452306
- Kasatpibal N, Whitney JD, Saokaew S, Kengkla K, Heitkemper MM, Apisarnthanarak A. Effectiveness of probiotic, prebiotic, and synbiotic therapies in reducing postoperative complications: a systematic review and network meta-analysis. Clin Infect Dis. 2017;64(suppl_2):S153–s160. doi:https://doi.org/10.1093/cid/cix114
- Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Ozaki T, Koga Y. Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. Surgery. 2014;155(3):493–503. doi:https://doi.org/10.1016/j.surg.2013.06.002
- Liu D, Jiang XY, Zhou LS, Song JH, Zhang X. Effects of probiotics on intestinal mucosa barrier in patients with colorectal cancer after operation: meta-analysis of randomized controlled trials. Medicine (Baltimore)). 2016;95(15):e3342 doi:https://doi.org/10.1097/md.0000000000003342
- Xu Q, Xu P, Cen Y, Li W. Effects of preoperative oral administration of glucose solution combined with postoperative probiotics on inflammation and intestinal barrier function in patients after surgery. Oncol Lett. 2019;18:694–8. doi:https://doi.org/10.3892/ol.2019.10336
- Liu Z-H, Huang M-J, Zhang X-W, Wang L, Huang N-Q, Peng H, Lan P, Peng J-S, Yang Z, Xia Y, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr. 2013;97(1):117–26.: doi:https://doi.org/10.3945/ajcn.112.040949
- Zhang J-W, Du P, Yang B-R, Gao J, Fang W-J, Ying C-M. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199–205. doi:https://doi.org/10.1097/MAJ.0b013e31823aace6
- Yang Y, Xia Y, Chen H, Hong L, Feng J, Yang J, Yang Z, Shi C, Wu W, Gao R, et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. 2016;7(7):8432–40. doi:https://doi.org/10.18632/oncotarget.7045
- Tan CK, Said S, Rajandram R, Wang Z, Roslani AC, Chin KF. Pre-surgical administration of microbial cell preparation in colorectal cancer patients: a randomized controlled trial. World J Surg. 2016;40(8):1985–92. doi:https://doi.org/10.1007/s00268-016-3499-9
- Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, Gilardini C, Zonenschain D, Nespoli A, Braga M, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16(2):167–75.:doi:https://doi.org/10.3748/wjg.v16.i2.167
- He D, Wang H-Y, Feng J-Y, Zhang M-M, Zhou Y, Wu X-T. Use of pro-/synbiotics as prophylaxis in patients undergoing colorectal resection for cancer: a meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2013;37(4):406–15. doi:https://doi.org/10.1016/j.clinre.2012.10.007
- Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, Giamarellos-Bourboulis EJ. A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015;39(11):2776–83. doi:https://doi.org/10.1007/s00268-015-3071-z
- Abbaszadeh H, Valizadeh A, Mahdavinia M, Teimoori A, Pipelzadeh MH, Zeidooni L, Alboghobeish S. 3-Bromopyruvate potentiates TRAIL-induced apoptosis in human colon cancer cells through a reactive oxygen species- and caspase-dependent mitochondrial pathway. Can J Physiol Pharmacol. 2019;97(12):1176–84. doi:https://doi.org/10.1139/cjpp-2019-0131
- Tiptiri-Kourpeti A, Spyridopoulou K, Santarmaki V, Aindelis G, Tompoulidou E, Lamprianidou EE, Saxami G, Ypsilantis P, Lampri ES, Simopoulos C, et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS One. 2016;11(2):e0147960. doi:https://doi.org/10.1371/journal.pone.0147960
- Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne-Muller G, Dimanche-Boitrel M-T, Jan G. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget. 2016;7(6):7161–78. doi:https://doi.org/10.18632/oncotarget.6881
- Bohlul E, Hasanlou F, Taromchi AH, Nadri S. TRAIL-expressing recombinant Lactococcus lactis induces apoptosis in human colon adenocarcinoma SW480 and HCT116 cells. J Appl Microbiol. 2019;126(5):1558–67. doi:https://doi.org/10.1111/jam.14237
- Singh S, Kotla NG, Tomar S, Maddiboyina B, Webster TJ, Sharma D, Sunnapu O. A nanomedicine-promising approach to provide an appropriate colon-targeted drug delivery system for 5-fluorouracil. Int J Nanomedicine. 2015;10:7175–82. doi:https://doi.org/10.2147/ijn.S89030
- Yin L, Meng Z, Zhang Y, Hu K, Chen W, Han K, Wu B-Y, You R, Li C-H, Jin Y, et al. Bacillus spore-based oral carriers loading curcumin for the therapy of colon cancer. J Control Release. 2018;271:31–44.:doi:https://doi.org/10.1016/j.jconrel.2017.12.013
- Krishnaiah YS, Khan MA. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer. Pharm Dev Technol. 2012;17(5):521–40. doi:https://doi.org/10.3109/10837450.2012.696268
- Devassy JG, Nwachukwu ID, Jones PJ. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev. 2015;73(3):155–65. doi:https://doi.org/10.1093/nutrit/nuu064
- Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E, Ciardiello F. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32. doi:https://doi.org/10.1016/j.ctrv.2019.04.003
- Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52. doi:https://doi.org/10.1016/j.immuni.2018.03.014
- Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75. doi:https://doi.org/10.1038/s41575-019-0126-x
- Chen Y, Huang Y, Lu X, Wang G, Chi P. Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation. Oncol Rep. 2018;40(6):3370–80. doi:https://doi.org/10.3892/or.2018.6738
- Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. doi:https://doi.org/10.1016/s1470-2045(17)30422-9
- Mohania D, Kansal VK, Kumar M, Nagpal R, Yamashiro Y, Marotta F. Modulation of expression of programmed death-1 by administration of probiotic Dahi in DMH-induced colorectal carcinogenesis in rats. Acta Biomed. 2013;84(2):102–9.
- Wang T, Zheng N, Luo Q, Jiang L, He B, Yuan X, Shen L. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front Immunol. 2019;10:1235. doi:https://doi.org/10.3389/fimmu.2019.01235 [InsertedFromOnline[pubmedMismatch]]